ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

0FDB Navamedic Asa

12.10
0.00 (0.00%)
28 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Navamedic Asa LSE:0FDB London Ordinary Share NO0010205966 NAVAMEDIC ORD SHS
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 12.10 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 382.14M 29.43M 1.7083 7.08 208.46M

Updated recommendation by the nomination committee of Navamedic ASA

31/05/2023 1:42pm

PR Newswire (US)


Navamedic Asa (LSE:0FDB)
Historical Stock Chart


From Jun 2022 to Jun 2024

Click Here for more Navamedic Asa Charts.

OSLO, Norway, May 31, 2023 /PRNewswire/ -- Following Navamedic ASA's acquisition of Sensidose AB, the nomination committee recommends that Åsa Kornfeld, previous Board member in Sensidose AB, is elected as a new Navamedic ASA Board member in addition to Terje Bakken (Chairman), Narve Reiten, Jostein Davidsen, Annika Kollén and Edmée Steenken on the Annual General Meeting on June 1st, 2023.

Åsa Kornfeld served as a Board member of Sensidose AB when Navamedic ASA acquired the company. She is Pricing & Access Lead in Recordati Rare Diseases based in Paris, and has extensive experience from the pharmaceutical industry, with more than 25 years of international experience. She holds an M.Sc Medicines and Healthcare products from Université de Bordeaux, and Finance for Executives from INSEAD.

On behalf of the nomination committee,
Bernt Olav Røttingsnes

For further information, please contact:

Kathrine G. Andreassen, CEO, Navamedic, Mobile: +47 951 78 680 E-mail: kathrine@navamedic.com 

Lars Hjarrand, CFO, Navamedic, Mobile: +47 917 62 842 E-mail: lars.hjarrand@navamedic.com

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/updated-recommendation-by-the-nomination-committee-of-navamedic-asa-301838605.html

Copyright 2023 PR Newswire

1 Year Navamedic Asa Chart

1 Year Navamedic Asa Chart

1 Month Navamedic Asa Chart

1 Month Navamedic Asa Chart